Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

St Johns wort increases expression of P-glycoprotein: implications for drug interactions.

Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back D, Mulcahy F, Feely J.

Br J Clin Pharmacol. 2002 Jan;53(1):75-82.

2.

MDR- and CYP3A4-mediated drug-herbal interactions.

Pal D, Mitra AK.

Life Sci. 2006 Mar 27;78(18):2131-45. Epub 2006 Jan 25. Review.

PMID:
16442130
3.

Clinical drugs that interact with St. John's wort and implication in drug development.

Di YM, Li CG, Xue CC, Zhou SF.

Curr Pharm Des. 2008;14(17):1723-42. Review.

PMID:
18673195
4.

Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.

Goey AK, Mooiman KD, Beijnen JH, Schellens JH, Meijerman I.

Cancer Treat Rev. 2013 Nov;39(7):773-83. doi: 10.1016/j.ctrv.2012.12.008. Epub 2013 Feb 8. Review.

PMID:
23394826
5.

In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.

Patel J, Buddha B, Dey S, Pal D, Mitra AK.

Am J Ther. 2004 Jul-Aug;11(4):262-77.

PMID:
15266218
6.

Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.

Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H, Hitzl M, Dresser GK, Kim RB, Kirch W.

Clin Pharmacol Ther. 2007 May;81(5):669-78. Epub 2007 Mar 28.

PMID:
17392718
7.

Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients.

Hennessy M, Clarke S, Spiers JP, Kelleher D, Mulcahy F, Hoggard P, Back D, Barry M.

Antivir Ther. 2004 Feb;9(1):115-22.

PMID:
15040543
8.

St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.

Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K.

Clin Pharmacol Ther. 2000 Dec;68(6):598-604.

PMID:
11180019
9.

No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract.

Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin HH, Friede M, Roots I.

Planta Med. 2005 Apr;71(4):331-7.

PMID:
15856409
10.

Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations.

Borrelli F, Izzo AA.

AAPS J. 2009 Dec;11(4):710-27. doi: 10.1208/s12248-009-9146-8. Epub 2009 Oct 27. Review.

11.

Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure.

Perloff MD, von Moltke LL, Störmer E, Shader RI, Greenblatt DJ.

Br J Pharmacol. 2001 Dec;134(8):1601-8.

12.

An update on clinical drug interactions with the herbal antidepressant St. John's wort.

Zhou SF, Lai X.

Curr Drug Metab. 2008 Jun;9(5):394-409. Review.

PMID:
18537576
13.

Effects of St. John's wort extract on indinavir pharmacokinetics in rats: differentiation of intestinal and hepatic impacts.

Ho YF, Huang DK, Hsueh WC, Lai MY, Yu HY, Tsai TH.

Life Sci. 2009 Aug 12;85(7-8):296-302. doi: 10.1016/j.lfs.2009.06.008. Epub 2009 Jun 24.

PMID:
19559714
14.

Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum).

Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I.

Clin Pharmacol Ther. 1999 Oct;66(4):338-45.

PMID:
10546917
15.

Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.

Hafner V, Jäger M, Matthée AK, Ding R, Burhenne J, Haefeli WE, Mikus G.

Clin Pharmacol Ther. 2010 Feb;87(2):191-6. doi: 10.1038/clpt.2009.206. Epub 2009 Nov 18.

PMID:
19924124
16.

The emerging recognition of herb-drug interactions with a focus on St. John's wort (Hypericum perforatum).

Markowitz JS, DeVane CL.

Psychopharmacol Bull. 2001 Winter;35(1):53-64. Review.

PMID:
12397870
17.

Drug interaction between St John's wort and zolpidem in healthy subjects.

Hojo Y, Echizenya M, Ohkubo T, Shimizu T.

J Clin Pharm Ther. 2011 Dec;36(6):711-5. doi: 10.1111/j.1365-2710.2010.01223.x. Epub 2010 Nov 8.

PMID:
21058968
18.

St John's wort (Hypericum perforatum): drug interactions and clinical outcomes.

Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P.

Br J Clin Pharmacol. 2002 Oct;54(4):349-56. Review.

19.

Pharmacokinetic interactions of drugs with St John's wort.

Zhou S, Chan E, Pan SQ, Huang M, Lee EJ.

J Psychopharmacol. 2004 Jun;18(2):262-76. Review.

PMID:
15260917
20.

Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression?

Gutmann H, Poller B, Büter KB, Pfrunder A, Schaffner W, Drewe J.

Planta Med. 2006 Jun;72(8):685-90. Epub 2006 Jun 1.

PMID:
16755466

Supplemental Content

Support Center